Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference62 articles.
1. King CT, Gegg CV, Hu SN, Sen Lu H, Chan BM, Berry KA, Brankow DW, Boone TJ, Kezunovic N, Kelley MR, Shi L, Xu C. Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor. ACS Pharmacol Transl Sci. 2019;2(6):485–90. https://doi.org/10.1021/acsptsci.9b00061.
2. European Medicine Agency. Aimovig [Internet]. https://www.ema.europa.eu/en/documents/product-information/aimovig-epar-product-information_en.pdf. Accessed 11 Oct 2020.
3. Garland SG, Smith SM, Gums JG. Erenumab: a first-in-class monoclonal antibody for migraine prevention. Ann Pharmacother. 2019;53:933–9.
4. Chaplin S. Erenumab: a monoclonal antibody for migraine prophylaxis. Prescriber. 2019;30:38–9.
5. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献